EP Patent

EP2377538A1 — Aqueous oral preparation of stable amlodipine

Assigned to MedRx Co Ltd · Expires 2011-10-19 · 15y expired

What this patent protects

The present invention aims to provide a stable aqueous oral preparation (liquid or jelly preparation) of amlosipine. The object aqueous oral preparation (jelly preparation) of amlodipine, which is stable and highly rapidly disintegratable, could be produced by using an anio…

USPTO Abstract

The present invention aims to provide a stable aqueous oral preparation (liquid or jelly preparation) of amlosipine. The object aqueous oral preparation (jelly preparation) of amlodipine, which is stable and highly rapidly disintegratable, could be produced by using an anionic surfactant having a sulfuric acid group or a sulfonic acid group as a stabilizer in an aqueous solution of amlodipine, preparing a liquid stable in the range of pH 5 - 7 as the liquid property, and adding and mixing a gelling agent, a fine powder solid and a gelling regulator. As a result, a novel oral preparation (liquid or jelly preparation) easy to take for older patients, who have declined swallowing function and face difficulty in taking tablets, can be provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP2377538A1
Jurisdiction
EP
Classification
Expires
2011-10-19
Drug substance claim
No
Drug product claim
No
Assignee
MedRx Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.